A common painkiller was designed to spare the stomach, but its safety story is more complicated

A common painkiller was designed to spare the stomach, but its safety story is more complicated
Image: Intellect (generated)

In short: Celecoxib was designed to ease pain and inflammation while sparing the stomach. Its story, from a patent fight to fabricated trial data and a long debate over heart risk, shows how hard it is to judge a drug fairly, even after it is approved and widely used.

Celecoxib, sold under the brand name Celebrex, belongs to a class called COX-2 inhibitors, a type of nonsteroidal anti-inflammatory drug. The enzymes COX-1 and COX-2 both help produce prostaglandins, chemicals involved in pain and inflammation. Older drugs such as aspirin, ibuprofen and naproxen block both enzymes. Celecoxib is about 10 to 20 times more selective for COX-2, which in theory eases inflammation and pain while causing fewer stomach ulcers, since COX-1 helps protect the stomach lining. It came into medical use in 1999 after being patented in 1993, and it is now sold as a generic medicine.

Its approved uses include osteoarthritis, rheumatoid arthritis, acute pain and painful menstruation. For postoperative pain it is roughly equal to ibuprofen. Its risks, however, are closer to other NSAIDs than its design suggested. A 2013 meta-analysis found that coxibs increased major cardiovascular problems by about 37% over placebo. A later randomized trial in 2016 found celecoxib was not more likely to cause poor cardiovascular outcomes than naproxen or ibuprofen, and in 2018 an FDA advisory panel concluded it carried no greater heart risk than those drugs. The evidence has been contested and continues to be weighed carefully.

The drug's history also includes serious questions about how evidence was reported. Pfizer and Pharmacia presented findings from a long-term arthritis study in 2000, but federal investigators found that only the first six months of a one-year trial had been reported, and later analysis did not confirm a significant reduction in stomach complications. In 2009 a former acute pain specialist admitted that data from 21 of his studies, covering celecoxib and other drugs, had been fabricated. Pfizer said it was unaware of the fraud, and none of those studies had been submitted to regulators.

Research has also looked beyond pain. Celecoxib has been tested as an add-on treatment for major depression, where a 2014 meta-analysis reported improved symptoms compared with placebo, while trials in bipolar disorder were inconclusive. It has also been studied for reducing polyps in familial adenomatous polyposis, where it reduced recurrence but raised serious cardiovascular concerns, and aspirin appears to offer a similar protective effect at much lower cost. The lesson is that a drug's intended mechanism does not guarantee its full effects, and that independent evidence matters.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/health-celecoxib.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…